Uncategorised - European Medical Journal

EMJ

ARAMIS trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…

EMJ

Immune checkpoint inhibitors and biomarker-driven strategies for managing lung cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen…

EMJ

An update on the treatment of chronic lymphocytic leukaemia

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephan Stilgenbauer, MD, of Ulm University, Ulm, Germany, reviews the changing…

EMJ

HELIOS: Phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory CLL

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY…

EMJ

IMAAGEN: Phase 2 trial of abiraterone acetate for advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides…

EMJ

CheckMate 067: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale…

EMJ

The evolving role of chemotherapy for the management of advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…

EMJ

Daratumumab for heavily pretreated multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta…

EMJ

Current clinical perspectives on targeted therapy and immunotherapy for melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France…

EMJ

ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the…